NGM Biopharmaceuticals (NYSE:NGM) was up 6.2% on Monday . The stock traded as high as $17.55 and last traded at $17.50, approximately 300,861 shares changed hands during mid-day trading. An increase of 146% from the average daily volume of 122,496 shares. The stock had previously closed at $16.48.

Several equities research analysts recently weighed in on NGM shares. B. Riley started coverage on shares of NGM Biopharmaceuticals in a research note on Thursday, October 17th. They issued a “buy” rating and a $24.00 target price for the company. Stifel Nicolaus reiterated a “buy” rating and issued a $26.00 target price on shares of NGM Biopharmaceuticals in a research note on Wednesday, August 14th. Finally, Zacks Investment Research upgraded shares of NGM Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Tuesday, August 27th. Six analysts have rated the stock with a buy rating, NGM Biopharmaceuticals currently has a consensus rating of “Buy” and an average target price of $24.17.

The business’s 50 day simple moving average is $13.47 and its 200 day simple moving average is $14.23.

NGM Biopharmaceuticals (NYSE:NGM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.11. The business had revenue of $21.57 million for the quarter, compared to the consensus estimate of $17.50 million.

In other NGM Biopharmaceuticals news, major shareholder Group L. P. Column sold 30,926 shares of the firm’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $77.72, for a total transaction of $2,403,568.72. Also, major shareholder Group L. P. Column purchased 53,172 shares of the business’s stock in a transaction on Friday, October 11th. The shares were acquired at an average price of $10.38 per share, with a total value of $551,925.36. In the last 90 days, insiders have acquired 264,922 shares of company stock valued at $2,872,650 and have sold 101,691 shares valued at $3,074,961.

A number of institutional investors and hedge funds have recently made changes to their positions in NGM. JPMorgan Chase & Co. bought a new position in shares of NGM Biopharmaceuticals in the second quarter valued at approximately $27,000. Nisa Investment Advisors LLC bought a new position in shares of NGM Biopharmaceuticals in the third quarter valued at approximately $81,000. Blackstone Group Inc bought a new position in shares of NGM Biopharmaceuticals in the second quarter valued at approximately $146,000. Bank of New York Mellon Corp bought a new position in shares of NGM Biopharmaceuticals in the second quarter valued at approximately $176,000. Finally, Citadel Advisors LLC bought a new position in shares of NGM Biopharmaceuticals in the second quarter valued at approximately $289,000.

About NGM Biopharmaceuticals (NYSE:NGM)

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.

Further Reading: Leveraged Buyout (LBO)

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.